Skip to main content
. 2021 Mar 22;13(6):1446. doi: 10.3390/cancers13061446

Figure 3.

Figure 3

Phenotypic assessment of the immune checkpoint in ILCs from patients treated with ipilimumab. Percentages of linCD7+ ILCs in live PBMCs from donors and patients following ipilimumab treatment at day 0, weeks 3, 6 and 12 (D0, W3, W6, W12) (A). Percentages of the different ILC populations in linCD7+ cells in patients following treatment (B). Expression of receptors in ILC populations in patients at D0 and at W12 of treatment (C). A Wilcoxon matched-pair signed rank test was used to compare percentages between D0 and other times of treatment (* p < 0.05, ** p < 0.01).